Unlearn.AI
AI platform that generates digital twins of clinical trial patients to reduce placebo arm size and accelerate drug trials.
What it does
Unlearn.AI is an AI-native clinical trial optimization company that creates 'digital twins' of clinical trial patients - AI-generated models that predict how specific patients would progress without treatment, based on their baseline characteristics and historical patient data. By using these digital twins as synthetic control arms, pharma companies can run clinical trials with smaller placebo groups, reducing patient exposure to ineffective treatments, accelerating trial timelines, and lowering trial costs. Unlearn's approach has received regulatory acceptance - the FDA and EMA have cleared the use of Unlearn's prognostic covariate methodology in specific trial designs - making it a scientifically credible approach to clinical trial optimization.
Why AI-NATIVE
Unlearn.AI is AI-native - digital twin patient modeling from clinical data and historical patient cohorts is the core product architecture, enabling a fundamentally new approach to clinical trial design.
Best for
Pharmaceutical and biotech companies use Unlearn.AI to reduce clinical trial costs and patient burden - AI-generated synthetic controls enabling smaller placebo arms while maintaining statistical power.
Limitations
Unlearn's methodology has regulatory acceptance in specific disease areas and trial designs — applicability to novel disease areas or unusual trial designs requires validation with regulatory agencies.
Digital twin generation accuracy depends on the depth and quality of historical patient data — rare diseases or novel patient populations with limited historical data produce less accurate digital twins.
Unlearn.AI addresses a specific problem in clinical trial design — its value is clear for late-stage drug development but limited for preclinical research or discovery-phase applications.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| Clinical data platform | Medidata |
| Drug discovery AI | Insilico Medicine |
| Genomic clinical data | Tempus |
Unlearn.AI does not publish standard pricing. Contracts with pharmaceutical companies are based on trial scope and disease area. Enterprise contracts typically start in the six-figure range per trial.
